Cidara Therapeutics, Inc. (CDTX)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CDTX Insider Trading Activity
CDTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $105,680 | 1 | 20 |
Sells | $96,814 | 4 | 80 |
Related Transactions
| Stein Jeffrey | President & CEO | 1 | $105,680 | 0 | $0 | $105,680 |
| Sandison Taylor | Chief Medical Officer | 0 | $0 | 1 | $10,752 | $-10,752 |
| Ward Shane | COO & CLO | 0 | $0 | 1 | $36,542 | $-36,542 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $49,520 | $-49,520 |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Insider Activity of Cidara Therapeutics, Inc.
Over the last 12 months, insiders at Cidara Therapeutics, Inc. have bought $105,680 and sold $96,814 worth of Cidara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cidara Therapeutics, Inc. have bought $207,124 and sold $66,716 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Stein Jeffrey (President & CEO) — $105,680.
The last purchase of 8,000 shares for transaction amount of $105,680 was made by Stein Jeffrey (President & CEO) on 2024‑06‑07.
List of Insider Buy and Sell Transactions, Cidara Therapeutics, Inc.
| 2025-03-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 1,773 0.0169% | $21.96 | $38,940 | +6.48% | |
| 2025-03-11 | Sale | Ward Shane | COO & CLO | 1,664 0.0159% | $21.96 | $36,542 | +6.48% | |
| 2024-09-11 | Sale | Sandison Taylor | Chief Medical Officer | 924 0.0128% | $11.64 | $10,752 | +71.60% | |
| 2024-09-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 909 0.0126% | $11.64 | $10,580 | +71.60% | |
| 2024-06-07 | Stein Jeffrey | President & CEO | 8,000 0.1804% | $13.21 | $105,680 | +2.10% | ||
| 2024-03-11 | Sale | Sandison Taylor | Chief Medical Officer | 20,662 0.0231% | $0.67 | $13,839 | -0.98% | |
| 2024-03-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 21,029 0.0235% | $0.67 | $14,085 | -0.98% | |
| 2024-03-11 | Sale | Shah Preetam | CFO & CBO | 18,931 0.0212% | $0.67 | $12,680 | -0.98% | |
| 2024-03-11 | Sale | Ward Shane | COO & CLO | 20,473 0.0229% | $0.67 | $13,713 | -0.98% | |
| 2023-09-11 | Sale | Sandison Taylor | Chief Medical Officer | 18,793 0.0205% | $0.95 | $17,810 | -27.31% | |
| 2023-09-11 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 18,469 0.0202% | $0.95 | $17,509 | -27.31% | |
| 2023-08-14 | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 10,000 0.0118% | $0.97 | $9,700 | -21.90% | ||
| 2023-08-08 | Stein Jeffrey | President & CEO | 50,000 0.0566% | $0.96 | $47,885 | -23.43% | ||
| 2023-03-27 | Stein Jeffrey | President & CEO | 50,000 0.0653% | $1.04 | $51,855 | -9.78% | ||
| 2023-03-13 | Sale | Sandison Taylor | Chief Medical Officer | 7,203 0.0081% | $1.53 | $11,021 | -45.66% | |
| 2023-03-13 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 7,562 0.0085% | $1.53 | $11,570 | -45.66% | |
| 2023-03-13 | Sale | Shah Preetam | CFO & CBO | 6,648 0.0075% | $1.53 | $10,171 | -45.66% | |
| 2023-03-13 | Sale | Ward Shane | COO & CLO | 4,329 0.0049% | $1.53 | $6,623 | -45.66% | |
| 2023-01-12 | Sale | Tari Leslie | CHIEF SCIENTIFIC OFFICER | 11,814 0.015% | $1.20 | $14,177 | -13.33% | |
| 2022-09-19 | Sale | Shah Preetam | CFO & CBO | 15,642 0.0226% | $0.77 | $12,035 | +38.16% |
Insider Historical Profitability
| Stein Jeffrey | President & CEO | 24580 0.2244% | $541,989.00 | 16 | 0 | <0.0001% |
| Sandison Taylor | Chief Medical Officer | 23067 0.2106% | $508,627.35 | 2 | 5 | +18.64% |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER | 16215 0.148% | $357,540.75 | 1 | 8 | <0.0001% |
| Ward Shane | COO & CLO | 14674 0.134% | $323,561.70 | 0 | 3 | |
| BIOTECH TARGET N V | 10 percent owner | 2295272 20.9547% | $50.61M | 1 | 0 | <0.0001% |
| Shah Preetam | CFO & CBO | 227210 2.0743% | $5.01M | 1 | 3 | <0.0001% |
| Daruwala Paul | Chief Operating Officer | 221099 2.0185% | $4.88M | 0 | 7 | |
| Kjellson Nina S | director | 200000 1.8259% | $4.41M | 1 | 0 | <0.0001% |
| Heron Patrick J | director | 155645 1.421% | $3.43M | 1 | 0 | <0.0001% |
| Forrest Kevin | Chief Scientific Officer | 72354 0.6606% | $1.6M | 3 | 0 | <0.0001% |
| Abdollahian Neil | Chief Business Officer | 57471 0.5247% | $1.27M | 0 | 5 | |
| Levine James E. | Chief Financial Officer | 50000 0.4565% | $1.1M | 2 | 0 | +33.09% |
| Johnson Brady | Vice President, Finance | 49366 0.4507% | $1.09M | 0 | 3 | |
| Franson Timothy R | director | 11000 0.1004% | $242,550.00 | 2 | 0 | <0.0001% |
| Oien Jessica | General Counsel & Secretary | 7764 0.0709% | $171,196.20 | 0 | 4 | |
| PEREZ ROBERT J | director | 5000 0.0456% | $110,250.00 | 1 | 0 | <0.0001% |
| BURGESS DANIEL D | director | 3000 0.0274% | $66,150.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$21,540,805 | 87 | 0.99% | $217.93M | |
$69,130,029 | 69 | 25.63% | $240.78M | |
$11,468,215 | 44 | 17.78% | $246.73M | |
$17,983,739 | 41 | 102.87% | $266.1M | |
$2,545,071 | 34 | 16.59% | $230.29M | |
Cidara Therapeutics, Inc. (CDTX) | $18,554,304 | 31 | -11.72% | $241.52M |
$41,069,367 | 23 | 54.64% | $211.17M | |
$56,550,550 | 22 | 50.17% | $270.11M | |
$3,513,995 | 18 | -13.04% | $229.96M | |
$2,081,205 | 17 | -20.90% | $211.4M | |
$46,754,287 | 15 | -19.17% | $267.07M | |
$11,230,365 | 11 | -45.81% | $218.05M | |
$145,296,407 | 8 | -0.98% | $215.31M | |
$94,000,000 | 7 | -20.84% | $234.78M | |
$317,601 | 5 | -23.48% | $249.07M | |
$11,194,630 | 4 | -22.97% | $255.36M | |
$4,888,000 | 3 | -20.50% | $246.36M | |
$149,309 | 3 | 6.07% | $275.28M | |
$102,796 | 1 | -21.40% | $263.42M |
CDTX Institutional Investors: Active Positions
| Increased Positions | 31 | +155% | 4M | +121.04% |
| Decreased Positions | 7 | -35% | 439,366 | -13.28% |
| New Positions | 17 | New | 3M | New |
| Sold Out Positions | 4 | Sold Out | 371,469 | Sold Out |
| Total Postitions | 44 | +120% | 7M | +107.76% |
CDTX Ownership Change vs Market
Institutional Investor Ownership
| Bvf Inc/Il | $27,211.00 | 9.94% | 1.09M | +389,731 | +55.43% | 2024-12-31 |
| Ra Capital Management, L.P. | $27,211.00 | 9.94% | 1.09M | +389,716 | +55.43% | 2024-12-31 |
| Tcg Crossover Management, Llc | $25,047.00 | 9.15% | 1.01M | +1M | New | 2024-12-31 |
| Vr Adviser, Llc | $19,067.00 | 6.96% | 765,723 | +765,723 | New | 2024-12-31 |
| Bain Capital Life Sciences Investors, Llc | $17,507.00 | 6.39% | 703,080 | 0 | 0% | 2024-12-31 |
| Vivo Capital, Llc | $16,698.00 | 6.1% | 670,600 | +670,600 | New | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $9,212.00 | 3.36% | 369,954 | +327,199 | +765.29% | 2024-12-31 |
| Vanguard Group Inc | $5,416.00 | 1.98% | 217,504 | +36,969 | +20.48% | 2024-12-31 |
| Checkpoint Capital L.P. | $4,904.00 | 1.79% | 196,949 | +14,523 | +7.96% | 2024-12-31 |
| Renaissance Technologies Llc | $2,381.00 | 0.87% | 95,617 | -2,200 | -2.25% | 2024-12-31 |